-
The Evolution of Pharma Depends on Data Integration and Application
The potential applications for this vast quantity and variety of data are nearly endless.
PAP-Q4-18-NI-001 -
The Coming of Age of Amorphous Solid Dispersions
Numerous drugs formulated as amorphous solid dispersions have been successfully commercialized.
PAP-Q4-18-CL-004 -
From Proof of Concept to Commercialization
Brammer’s vision is to be the leading CDMO for viral vector supply to cell and gene therapy innovators.
PAP-Q4-18-CL-003 -
Knowledge and Experience Equal Successful Technology Transfer
Technology transfer should result in the transfer of product and process knowledge into a new phase of the life cycle.
PAP-Q4-18-CL-008 -
A Turnkey Solution: Sourcing Equipment and Empowering Operators
We offer a turnkey solution by sourcing equipment that meets production line requirements.
PAP-Q4-18-CL-007 -
Designing Effective Facilities to Meet the Growing Demand for Oligonucleotide Drugs
An oligo drug manufacturing facility incorporates aspects of small-molecule and biologic drug facilities.
PAP-Q4-18-CL-002 -
Regulatory Spotlight: FDA Delays Enforcement of Serialization Mandate
The FDA issued new guidances regarding enforcement of the DSCSA's track and trace mandate.
PAP-Q4-18-NI-011 -
Big Data in Drug Development and Discovery
Companies that apply the data will have a competitive advantage in drug discovery and development.
PAP-Q4-18-NI-006 -
Big Data in Drug Manufacturing
To achieve cohesive data integration in drug manufacturing, systems must be aligned.
PAP-Q4-18-NI-005 -
Big Data in Drug Packaging and Distribution
The emphasis on serialization is a tangible move toward making post-market data mining more robust.
PAP-Q4-18-NI-004 -
Preparing Clinical Trial Logistics for a No-Deal Brexit
Pharmaceutical companies should prepare for Brexit by mitigating their supply chain risks.
PAP-Q4-18-CL-006 -
Drug Repositioning: Facilitating Drug Repositioning with Artificial Intelligence
Computer-based approaches are essential to enable systematic drug repositioning efforts.
PAP-Q4-18-NI-009 -
The Value of Complementary Specialized Capabilities
Continued investment in innovations that address the needs of current and next-generation therapies is essential.
PAP-Q4-18-CL-001 -
Risk Minimization with an Integrated Global Network
Collaborating with an embedded organization with an integrated, global network can facilitate access to growing markets.
PAP-Q4-18-CL-005 -
Preparative Chromatography
Servier’s InnoPreP™ technology offering appeals to mid-size pharmas who need to quickly move their project into clinical studies .
PAP-Q4-18-NI-002 -
New Drug News: Regulatory Approval Brings siRNA into the Rare Disease Toolbox
siRNA joins the other nucleic acid–based drugs entering the marketplace for the treatment of rare diseases.
PAP-Q4-18-NI-010 -
Foreign Investment: Chinese Capital Backs U.S. Biotech
Given the amount of Chinese capital and the growing interest in the segment, the market feels unlimited.
PAP-Q4-18-NI-008 -
Q: What Innovative Technologies Had the Greatest Impact on your Company this Year? What Were the Impacts?
Industry leaders discuss recent technological innovations.
PAP-Q4-18-NI-007 -
Q: Looking Forward, What New Technologies/Paradigms Do You Anticipate Having the Greatest Impact Next Year (Digitalization and Industry 4.0, Serialization, etc.)?
Industry leaders discuss forthcoming technological innovations.
PAP-Q4-18-NI-003
-
Strengthening the Outsource Service Offering through Integration
Controlling costs and increasing efficiencies are two fundamental drivers for outsourcing of pharmaceutical manufacturing, explains Luigi Trussardo, CEO of Olon Ricerca Bioscience.
-
How to Tell If You’re Using a Quality Hard Capsule
Bahi Mahesan, Regulatory Affairs and Quality Manager for CapsCanada, explains the benefits of using a high-quality supplier for hard-shell capsules.
-
Five Tips to Ensure Faster Equipment Procurement and Installation
Used equipment is readily available, cuts lead time for delivery and install, and allows faster product launch, says Jim Coyne, Business Development/Sales at Federal Equipment Company.
-
Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing
Ariana Nagel, Director of Product Development, R&D and and Matthew Ferrell, Director of Analytical Development at UPM Pharmaceuticals explain the benefits and challenges of peptide therapies.
-
Addressing the Challenges and Opportunities Presented by Advanced Therapies
Phacilitate Leaders World, World Stem Cell Summit (WSCS), Cell & Gene Therapy World, Immuno-Oncology Frontiers World and Cord Blood & Perinatal Stem Cells Summit conferences to be held at the Hyatt Regency Miami, January 22-25, 2019.
-
From Proof of Concept to Commercialization
Mark Bamforth, CEO and Richard Snyder, CSO, explain how Brammer Bio is investing to support the commercial development of gene and cell therapies.
-
FDA Approves First Inhaler with Built-in Sensors
Teva Pharmaceutical Industries integrated digital rescue inhaler connects to a smartphone app.
-
Allergan Establishes R&D Group in Massachusetts
Kendall Square site will allow Allergan to connect with venture capital groups and startups in Cambridge.
-
Longeveron Receives Prestigious NIH Small Business Innovation Research Grant
Grant will be applied to Longeveron’s Aging Frailty stem cell research.
-
Experimental Treatment Approach Shows Potential against Staphylococcus aureus
A new class of engineered proteins may counter infection caused by Staphylococcus aureus – a bacterial species considered one of the largest global health threats.
-
Dedicated CDMO Services Meet Customer Needs in the Dynamic Biopharma Sector
Federico Pollano, Senior Vice President Business Development, Rentschler Biopharma SE, outlines the advantages of a dedicated CDMO.
-
Hard-Shell Capsule Solutions for Sensitive Compounds: A Focus on Probiotics
Eli Elias, Director of Business Development for CapsCanada explains why hard-shell capsules designed to degrade under specific conditions are a better option for probiotics.
-
Meeting Biopharma Contract Manufacturing Needs with a Flexible Global Network
Gustavo Mahler, President & CEO of AGC Biologics discusses the increasing need for CDMO support to provide with advanced capabilities and technology platforms across scales and geographies.
President & CEOAGC Biologics -
Fully Supporting Customer Needs for Biologics Development and Manufacturing
James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.
-
Remembering the Details: Partnering with an Equipment Supplier During a Merger or Acquisition
Justin Kadis, Business Development for Federal Equipment Company explains how to deal with asset management issues following a merger or acquisition.
-
Biotech Company Stealth BioTherapeutics Files for IPO
Stealth BioTherapeutics hopes to raise $86 million in a Nasdaq IPO to fund development of mitochondrial dysfunction drug.
-
Antengene Benefits from Second-Round Financing
The Chinese biotech raises $120 million.
-
Newly Discovered Phagocyte Plays Role in Autoimmune Disease
Hemophagocytes, a newly identified population of phagocytes, may have a direct impact on patients with a variety of autoimmune diseases.
-
China Cancer Drugs Market 2018-2024: Rising Demand of Targeted Drug Therapy and the Patent Expiration of Key Cancer Drugs
The Chinese cancer drug market is projected to reach US$ 30 Billion by the year 2024.
-
Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies
Oliver Technow, President of BioVectra, explains the necessity of forward-thinking CDMOs.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestAddressing the Challenges and Opportunities Presented by Advanced Therapies
Jan 15, 2019 5:09:05 PM PAO-M01-19-NI_CL-001Researchers Identify Potential Approach for Treating the Toughest Breast Cancer
Jan 9, 2019 4:13:58 PM PAO-M01-19-NI-013New Assays for Detecting Genomic Mutations Launched by Contextual Genomics
Jan 8, 2019 10:58:34 AM PAO-M01-19-NI-005Remembering the Details: Partnering with an Equipment Supplier During a Merger or Acquisition
Jan 8, 2019 10:06:55 AM PAO-M01-19-CL-001
TOPICS
View All TopicsPRESS RELEASES
View All-
AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial
Jan 18, 2019 5:00:00 AM -
Experimental Treatment Approach Shows Potential against Staphylococcus aureus
Jan 18, 2019 5:00:00 AM -
Longeveron Receives Prestigious NIH Small Business Innovation Research Grant
Jan 18, 2019 5:00:00 AM -
Longeveron Recruiting For Stem Cell Alzheimer’s Trial In South Florida
Jan 18, 2019 5:00:00 AM -
New Analytic Model to Better Identify Patients Likely to Develop PTSD
Jan 17, 2019 5:00:00 AM -
ProKidney Announces $62 million Acquisition of inRegen
Jan 17, 2019 5:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
